Discover the impact of cryopreservation of PBMCs on T cell activation and phenotype in Lonza’s free webinar.
Human peripheral blood mononuclear cells (PBMCs) consisting of lymphocytes, dendritic cells and monocytes play an important role in both innate and adaptive immune systems. As such, PBMCs are increasingly being used in the drug development of biological therapeutics. Should you be concerned how cryopreservation will affect the various sub-populations of immune cells contained in your PBMC sample or performance parameters of those cells? Are you looking for more convenience in your immunology research workflows? Lonza scientists investigated what possible effects cryopreservation could have on the functionality of PBMC samples.
Key Topics Include:
- T cell proliferative response is not altered by cryopreservation
- Cryopreservation does not change pro- or anti-inflammatory cytokines secretion profiles
- Cryopreservation does not alter the percentages of cell populations in PBMCs
- The data supports the more convenient use of cryopreserved PBMCs over freshly isolated cells
- Categories: Cell & Molecular Biology, Drug Discovery & Development, Microbiology & Immunology
- Tags: cytokines, peripheral blood mononuclear cell (PBMC), t cells
Presenters
Aurita Menezes, PhD
Sr. Market Development Manager
Lonza
Aurita Menezes, PhD is a Sr. market Development manager within the Marketing team at Lonza. In her role she is responsible for identifying products and product improvements that will serve the biologics and preclinical markets. Her portfolio focuses on hematopoietic immune and stem cells. She works closely with the Lonza R&D team to drive innovation with new primary cell products and assays. Aurita received her PhD in Microbiology and Immunology from University of Mississippi where she researched the major histocompatibility complex of Ictalurus punctatus. Previous to her role at Lonza she was a Sr. product manager at Integrated DNA technologies leading the development of qPCR gene expression and genotyping products.
Katherine Dunnick, PhD
MSAT Principal Process Engineer
Lonza
Katherine (Katie) Dunnick, PhD is a Principal Process Engineer within the MSAT team at Lonza where she focuses on process improvement projects. Prior to her work in MSAT, she was a member of the Lonza R&D team working on the development of new primary cell products and assays. Katie received her PhD in Pharmaceutical and Pharmacological Sciences from West Virginia University where she researched the effects of nanoparticles on pulmonary systems, both in vitro and in vivo. After completing her PhD, she joined ScitoVation where she developed a novel assay to detect double strand DNA breaks via flow cytometry. She then joined MatTek as a Business Development/Marketing Manager prior to joining the Lonza MSAT team.
Sarah Thacker, PhD
Senior Scientist II
In Vitro Pharmacology
SpringWorks Therapeutics
Sarah Thacker, PhD is a former Principle Scientist in the cell biology R&D group, at Lonza’s Center for Cell Excellence in Durham, NC, USA. While at Lonza Sarah lead R&D project initiatives to enable new product development as well as improvement upon existing products in the cell biology portfolio. Prior to working at Lonza, Sarah was a Biology Lead at Vitrisa Therapeutics, which involved developing biochemical and cell-based assays to screen and advance lead compounds targeted to treat ocular indications. Sarah holds a Ph.D. in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, and a Bachelor of Science in Chemistry from Washington College.
Production Partner
Lonza Group AG
Lonza Bioscience provides life science researchers worldwide with the tools they need to develop and test critical disease-treating drugs and therapies, from basic research to final product release, including cell culture and discovery technologies, quality control tests and software for biomanufacturing.
Additional Content From Scientist.com
Circulating Nucleosome Quantification (Nu.Q®) Technology for Monitoring Target Engagement and Adverse Events in Oncology Trials
Join us for a comprehensive webinar featuring experts in epigenetics and assay development, focusing on the scientific foundations and applications of Nucleosome Quantification (Nu.Q®) Technology in the realms of drug development and disease monitoring.
Innovative Approaches to Assessing Thyroid Disruption: The 3D Human Thyroid Microtissue Model
Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models.
Preclinical Animal Models of IBD, GVHD, and Pulmonary Disease
Join BioModels’ Scientists, Andrew Borkowski, PhD and Nicole Smith, PhD, as they discuss a selection of key preclinical models of inflammatory disease, including models of Inflammatory Bowel Disease (IBD)/colitis, Graft vs Host Disease (GvHD), and pulmonary disease, focusing on the utility of clinically relevant endpoints that create highly translational models of human disease.
Related Content
Clambake: An Algorithm to Decode Energy Expenditure Data from Metabolic Cages
In this webinar, Dr. Jonathan Brestoff discusses his research on metabolism and a new method to quantify metabolic data known as Clambake.
Molecular Signals Mediating Increases in Muscle Size and Function
In this webinar, Dr. Bert Blaauw elucidates skeletal muscle regulatory pathways and offers approaches to tackle muscle deficits for therapy.
Applications of Human Intestinal Organoid Cultures in Drug Discovery
Join STEMCELL TEchnologies' experts as they discuss the use of human intestinal organoid cultures in drug discovery and toxicity testing.
